Company intelligence / Profile preview
Chengdu Phargentech Technology
Chengdu, Sichuan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Chengdu Phargentech, as part of Kanghong Pharmaceuticals Group, is involved in developing new drugs and therapeutic platforms, especially in psychosis, neurosis, digestion, respiration, incretion, and tumors. The group reports successful development and marketing of over 20 new drugs and ongoing research on several Class-I drugs, including anti-tumor medicines and ophthalmological genetic medicines[1].
- Therapeutic areas
- EndocrinologyGastroenterologyPulmonologyPsychiatryOncology
- Modalities
- Small moleculeBiologicProteinMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sagent Pharmaceuticals (joint venture for manufacturing)
Beyond the preview
Go deeper on Chengdu Phargentech Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Phargentech Technology.